Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor HSD-1 Inhibitor Clofutriben (SPI-62) for Polymyalgia Rheumatica at the European Congress of Rheumatology 2024

2024-06-06

临床2期临床结果

Presentation will describe how clofutriben modulates key biomarkers of prednisolone efficacy and toxicity in patients with polymyalgia rheumatica. Sparrow’s Chief Scientific Officer will describe new insights about glucocorticoid action on the 75th anniversary of glucocorticoid utilization for treatment of rheumatic diseases. PORTLAND, Ore.--(BUSINESS WIRE)-- Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitor HSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?” Sparrow’s Founder and Chief Scientific Officer will describe how clofutriben modulates key biomarkers of prednisolone efficacy and toxicity in his presentation, "The 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 Differentially Modulates Prednisolone Immune and Musculoskeletal Efficacy and Bone Formation/Resorption Biomarkers in Patients with Polymyalgia Rheumatica (PMR): An Interim Report.” Presenter: Dr. David Katz, Ph.D., Chief Scientific Officer, Sparrow Pharmaceuticals Session Location: Room C7 Session Time: 15 June 2024 at 12:50 CEDT To learn more about Sparrow Pharmaceuticals clofutriben, visit . About Sparrow Pharmaceuticals Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, clofutriben (SPI-62), is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构